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1. Introduction 
The term “probiotic” was only coined starting from 1953 and means “for life” (“pro = for” 
and “bios = life”) as opposed to “antibiotics”. Yet, the related concept dates back to the early 
1900s when Tissier and Metchnikoff pioneered the notion that not all bacteria are 
detrimental and that some may even be ingested for benefit of health and longevity (Tissier, 
1906; Metchnikoff, 1908). Since then, over 9000 articles and 700 clinical trials have been 
devoted to document and unravel the beneficial effects attributed to probiotic strains and 
the mechanisms of action that may be involved. The health benefits attributed to probiotics 
are numerous (Nomoto, 2005; Nova et al., 2007; O'Hara and Shanahan, 2007; Parvez et al., 
2006; Salminen et al., 2005; Sanders, 2008; Santosa et al., 2006) but the level of proof 
supporting them is highly variable depending on the benefit and more importantly on the 
studied strain. In view of the large diversity and the high number of probiotic candidate 
strains it is important to stress that most observations are strictly strain specific which 
means that data obtained on a given strain may not be extrapolated to all strains belonging 
to the corresponding bacterial species and genus. This renders a global analysis of the field 
quite difficult and general conclusions often lack accuracy. 
2. Human gut microbiota 
The adult human gastro-intestinal tract (GIT) houses about 1014 microbial cells, that 
outnumber by a factor of 10 the number of cells that compose the human body. This 
complex microbiota contains over 1000 bacterial types whose number and composition vary 
along the GIT as a consequence of the different biochemical conditions in the intestine, 
nutrient availability, age and health status of the host. Of note, the corresponding pool of 
genes (microbiome) is 150 times larger than the human genome (Eckburg et al., 2005). For 
this reason, the gut microbiota is sometimes referred to as an organ by itself. It is well 
established today that this complex microbial community plays an essential role in health 
and well being. Research conducted with germ-free or gnotobiotic (i.e. germ-free animals 
that were colonized by known bacteria) rodents has unambiguously demonstrated that even 
if germ free animals are viable when housed in specific conditions and fed with a very 
nutritious diet, the gut microbiota plays a critical role for normal growth and development 
(Kelly et al., 2007; Sjogren et al., 2009). 
The GIT of mammals is sterile at birth but it becomes rapidly colonized by maternal and 
environmental bacteria during the delivery. The successive installation of bacterial species 
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has been well studied (Fanaro et al., 2003; Salminen and Gueimonde, 2005) and was shown 
to be influenced by several factors such as the mode of delivery and the neonate’s diet 
(Laubereau et al., 2004; Martindale et al., 2005; Negele et al., 2004; Sicherer and Burks, 2008; 
Zutavern et al., 2006). The next critical phase of bacterial colonization occurs around 
weaning, when new foods are progressively introduced in the infant’s diet. A more complex 
microbiota is then established that evolves towards the typical adult one over the following 
years. The progressive bacterial population of the infant intestines has been shown to be of 
prime importance in the development of a mature gut ecosystem and a functional mucosal 
immune system. The GIT corresponds to a huge mucosal surface (close to 200 m2 in the 
adult) that is constantly challenged by external factors such as food components, microbes, 
toxic compounds, chemicals etc. and as such is one of the principal point of entry of 
pathogens. The GIT thus developed into a sophisticated organ that is able to discriminate 
between harmful and harmless agents, with an immune system that rapidly mounts defensive 
responses against infectious microbes while being able to tolerate food or self antigens. This 
exquisite level of regulation is progressively established as a result of bacterial stimulus 
including gut microbial colonization in early stages of life. The “hygiene hypothesis” 
postulates that the lack of adequate microbial challenge linked to modern living conditions in 
westernized countries is at the origin of the increasing prevalence of chronic immune 
dysfunctions such as inflammatory bowel disease and allergy (Ege et al., 2008; Schaub et al., 
2006; Waser et al., 2007). This postulate is the rationale behind the use of probiotic 
microorganisms to promote, restore or maintain a healthy status in humans and animals.  
3. Probiotics and health related benefits 
Probiotics have been defined by a FAO/WHO expert group as « live microorganisms which 
when administered in adequate amounts confer a health benefit on the host » (2001). This is 
the most widely accepted definition even if others - that are relatively similar- can be found 
in literature. This definition implies that the microorganisms are not restricted to bacteria, 
and yeasts such as Saccharomyces boulardii/cerevisiae for example have been studied for their 
health promoting properties. Typically S. boulardii probiotic preparations are 
commercialized as over the counter (OTC) products to fight diarrhea. Yet, most of the 
probiotic research has been conducted with lactobacilli and bifidobacteria, even though one 
strain of Escherichia coli, E. coli Nissle 1917, and a few strains of Enterococcus and Bacillus have 
also been well studied during the last decades. Today, the search for new health promoting 
microorganisms is extending beyond bacteria isolated from humans to strains originating 
from fermented food and feed products such as Pediococcus, Propionobacterium and 
Lactococcus spp. The bacterial genera Lactobacillus, Enterococcus, Pedicoccus, Propionibacterium, 
Streptococcus and Lactococcus belong to the family of lactic acid bacteria (LAB) which - as 
indicated by their name - are able to rapidly transform fermentable carbohydrates in 
substantial amounts of lactic acid, eventually accompanied by acetic and propionic acid, and 
butyrate. The capacity of lowering the environmental pH and thus creating an unfavorable 
milieu for specific pathogens is at the origin of the use of LAB for the preparation and 
preservation of fermented food and feed products since time immemorial. As a 
consequence, several LAB species have a “generally-recognised-as-safe” (GRAS) status in 
the food industry due to their long history of safe human consumption. Several species are 
also part on the endogenous mammal microbiota and can naturally be found in the oral, 
intestinal and urogenital tracts of healthy individuals. The number of specific genera of LAB 
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varies along the gastro-intestinal ecosystem and lactobacilli are typically dominant members 
of the human vaginal microbiota where they play a key protective role against infections 
(Falagas et al., 2007). 
The health benefits addressed by probiotic research are ranging from their anti-microbial 
properties to the impact probiotics may have on the host immune system and gut barrier, 
and on the metabolism and composition of the endogenous microbiota, and as a 
consequence on the host physiology. The applications are nowadays extending to extra-
intestinal sites such as the skin, the oral cavity, the urogenital tract and importantly the gut-
brain axis. Targeted diseases include bacterial and viral infections, chronic immune 
disorders such as allergy, inflammatory bowel disease and autoimmune diseases, irritable 
bowel syndrome, energy and weight management, mood disorders, stress and even 
psychological disorders such as autism (Asahara et al., 2001; Bin-Nun et al., 2005; Brenner et 
al., 2009; Carroll et al., 2007; Chapat et al., 2004; Cryan and O'Mahony, 2011; Dani et al., 
2002; Iovieno et al., 2008; Madsen et al., 2001; Zareie et al., 2006). From an experimental 
point of view, the major challenge is to select the most appropriate candidate probiotic 
strain(s) to reach the selected aim. Therefore, a series of in vitro and ex vivo assays are used 
before testing a limited number of strains in animal models mimicking the human disease. 
Even if time consuming this preclinical research is aiming at facilitating the clinical studies 
that are mandatory to support the health claim that may be attributed to a probiotic strain. 
In the past several selection criteria have been applied such as origin of the strain, acid and 
bile resistance, adhesion to epithelial cells etc., which today rather serve for characterization 
of candidate probiotic strains (Mercenier et al., 2008). Nowadays, safety and stability of the 
strains are considered as the main criteria that may lead to exclusion of strains for further 
applications (Delgado et al., 2008; Grimoud et al., 2010; Gueimonde and Salminen, 2006; 
Kalliomaki et al., 2010; Niers et al., 2007).  
4. Probiotics and immune modulation 
Probiotics are able to interact at different levels with the host intestinal ecosystem. They may 
exert effects in the gut lumen via the release of soluble active compounds (metabolites, 
enzymes), by co-aggregation with pathogens and by intensive cross-talk with the 
endogenous microbiota (Ait-Belgnaoui et al., 2006; Boirivant and Strober, 2007; Ewaschuk et 
al., 2008; Haller et al., 2001). They are also known to interact with the intestinal epithelial 
barrier and its associated mucus, and to initiate immune signaling (Vesterlund et al., 2006; 
Ohland and MacNaughton, 2010).  Specific probiotics are able to exert an effect beyond the 
gut, influencing the systemic immune system as well as other cell and organ systems, such 
as liver and brain. For example, certain strains were shown to interact with the enteric 
nervous system and as such to trigger the gut-brain axis (Cryan and O'Mahony, 2011; 
Duncker et al., 2008). 
Even though we are far from having identified all active compounds that may mediate these 
interactions, it has been undoubtedly established that bacterial cell surface associated 
molecules are recognized by the gut immune system. The cell wall of gram-positive bacteria 
– to which most probiotic bacteria belong – differs from that of gram-negative bacteria by a 
higher content in peptidoglycan, by the absence of lipopolysaccharides (LPS) and presence 
of a variety of lipoteichoic acids (LTA) or wall teichoic acids (WTA) instead. In both gram-
positive and gram-negative bacteria the cell surface may also be decorated by 
exopolysaccharides (EPS) and/or glycosylated proteins. Altogether these cell surface 
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components correspond to Microbial Associated Molecular Patterns or MAMPs (also named 
PAMPS for pathogenic microbes) that may differ substantially from one strain to another. 
MAMPS are known to bind to specific receptors, the pattern recognition receptors or PRRs, 
which are expressed by many immune cells and tissues such as the gut epithelium. The 
binding of MAMPs to PRRs explains how probiotic, commensal or pathogenic bacteria can 
elicit innate and adaptive immune responses in the host by triggering signaling cascades 
that in turn lead to the production of cytokines, chemokines and other innate effectors 
(Abreu, 2010; Kawai and Akira, 2010; Wells et al., 2010). The PRRs belong to three major 
families: the Toll-like receptors (TLRs), retinoic acid inducible gene I (RIG-I)-like receptors 
and nucleotide oligomerization domain-like (NOD) receptors (Kawai and Akira, 2010). The 
TLR and NOD receptors have been shown to play a role in immune activation by probiotics 
and commensals and so to influence skewing of naïve T cells, regulation of regulatory T 
cells (Tregs) and activation of antigen presenting cells (APCs) such as dendritic cells (DCs) 
and macrophages. Activated DCs produce different cytokines in response to different 
bacterial stimuli and this has consequences for the induction of different T cell subtypes 
(Baba et al., 2008; Mohamadzadeh et al., 2005). In this sense it is not surprising that different 
candidate probiotic strains exhibit different immune modulation specificities as they may 
carry varying MAMPs (Wells, 2011).  
Several studies have demonstrated that in vitro cytokine profiles elicited from PBMCs, DCs 
or macrophages vary substantially depending on the species but importantly also on the 
strain (Wells et al., 2011). Typically, Meijerink et al. recently compared the DC response to 
stimulation by 42 Lactobacillus plantarum strains and amounts of IL-10 and IL-12 levels 
showed up to 39 and 600 fold differences, respectively (Meijerink et al., 2010). This indicates 
that multiple factors play a role in determining the immune phenotype of a strain. Using 
genome comparison of L. plantarum strains and gene deletion techniques, bacterial genetic 
loci involved in these specific immune properties could be identified (Marco et al., 2009; 
Meijerink et al., 2010).  
The impact of the LTA has also been highlighted by genetic studies dealing with different 
Lactobacillus species, for example the composition of LTA in L. plantarum NCIMB8826 and 
Lactobacillus rhamnosus GG (Grangette et al., 2005; Perea et al., 2007), and presence/absence 
of LTA in Lactobacillus acidophilus NCK56 (Mohamadzadeh et al., 2011) was shown to 
influence the pro- or anti-inflammatory properties of the wild type and mutant strains. 
These are examples of studies that combined bacterial physiology and genetics with in vitro 
immune assays in order to generate a hypothesis that could be tested in animal models. 
They illustrate a nowadays quite active and rapidly evolving field of research.  Recent 
reviews have captured the information that has been gathered on how probiotics can signal 
through TLR2, TLR2/6, TLR4, TLR9, NOD 1 & 2, and other signaling pathways (Lebeer et 
al., 2010; Wells et al., 2011). 
Different lactobacilli and bifidobacteria have been reported to enhance or restore the barrier 
function (Resta-Lenert and Barrett, 2003; Ulluwishewa et al., 2011). In vivo data support 
these observations, which were recently reinforced in a human study showing that tight 
junction proteins of the gut epithelium (biopsies) were regulated upon perfusion of L. 
plantarum WCFS1 in the duodenum of healthy volunteers (Karczewski et al., 2010). 
Even though a lot of research has been dedicated to identify which cell surface molecules are 
operational in the probiotic-host interaction, other molecules such as DNA (Rachmilewitz et 
al., 2002; Rachmilewitz et al., 2004), metabolites or secreted soluble factors have also been 
established to play a key role. For example, soluble factors of Bifidobacterium breve C50 were 
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demonstrated to participate to the anti-inflammatory properties of the strain and to impact 
on intestinal ion channels (Heuvelin et al., 2010). 
While providing an exhaustive review of this area is beyond the scope of the chapter, it 
might be concluded that the use of a variety of in vitro and in vivo immune models linked to 
a good knowledge of bacterial physiology and genetics allowed progress in understanding 
the mechanisms of action of specific probiotic strains and identification of certain effector 
molecules. Nevertheless, efforts should be continued in this area while it will also be 
necessary to fill the major gap that remains between preclinical and clinical research. 
5. Atopic dermatitis (AD): Physiopathology of AD 
Atopic dermatitis or atopic eczema (AD/AE) is a chronic inflammatory disease of the skin, 
which usually occurs in the early years of life. The skin in AD is extremely dry and itchy and 
is inflamed - this leads to the characteristic redness, swelling, and scaling pattern often seen 
in the face and at flexural surfaces of the extremities of patients suffering from AD. AD has 
been divided in at least 2 different forms: (i) IgE associated or extrinsic dermatitis; (ii) non-
IgE associated or intrinsic dermatitis.  
Based on epidemiological and immunological studies, the natural history of AD seems to 
follow three phases: an initial non-atopic (non-IgE associated) form of eczema occurring in 
the early infancy followed in 60 to 80% of the cases by a sensitization to food and /or 
environmental allergens with the development of associated IgE (true AD). Finally, an IgE 
sensitization to self-proteins is observed in a high proportion of children and adults with 
AD due to molecular mimicry (Bieber, 2008). 
 
Atopi
Non I
c derma
gE-asso
Barrier 
titis (A
ciated
Hypoth
No Ig
indu
aggre
D)
esis 
E, 
ced by
ssion
A
 skin 
I
S
f
topi
Acqu
gE-ass
ympt
ood al
c de
ired Sen
ociate
oms in
lergen
rmat
sitizat
d AD
crease
s
itis (
ion 
,
 with
Immun
AD)
 
ologic H
Ig
F
in
A
I
ypoth
E ass
ood al
duce 
topic 
gE-asso
esis 
ociate
lergen
sympt
dermat
ciated
d AD
s 
oms
itis (AD)
 
Fig. 1. AD classification (Bieber, 2008) 
AD is often the first disorder to manifest in the relay of allergies, usually referred to as the 
Atopic March (Hahn and Bacharier, 2005; Illi et al., 2004; Spergel and Paller, 2003; Zheng 
et al., 2011). The prevalence of the disorder has increased dramatically in the last two 
decades similar to other allergies such as allergic rhinitis and asthma. AD affects mostly 
infants and young children and according to recent epidemiological studies, 5-20% of 
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children are affected in developed countries (Asher et al., 2006; Williams et al., 1999). The 
treatment of AD is mainly symptomatic and includes emollients to moisturize the skin, 
and topical corticosteroids along with a switch to an elimination diet (BuBmann et al., 
2009; Peserico et al., 2008). 
AD has a complex etiology. Recent investigations into mechanisms that drive the 
inflammatory response in AD have highlighted the crucial role of genetic predisposition.  
Many mutations have been associated to the development of AD. These mutations are located 
in two subsets of genes, in structural protein genes involved in the epidermal-barrier function 
or in genes involved in IgE production (Bieber, 2008; Demehri et al., 2009; Hsu et al., 2008; 
Suzuki et al., 2011). Also, environmental factors can contribute to the development of AD. As 
such, AD can be classified into IgE-mediated and non IgE-mediated subtypes (Fig. 1.).   
As mentioned above, it has been postulated (“hygiene hypothesis”) that the pattern of 
bacterial colonization of the gut during the early months after birth can contribute to the 
development of AD (Vael and Desager, 2009). During the first year of life the newborn 
immune system is still under development while exposure to novel dietary foods is 
increasing, especially around the weaning period. These multifactorial events in concert 
contribute to the establishment of oral tolerance, i.e. prevention or development of atopic 
sensitization to common foods such as cow’s milk, eggs, wheat and nuts that predispose to 
the development of AD (Garcia et al., 2007; Gonzalez, I et al., 1971; Han et al., 2004; 
Heratizadeh et al., 2011). 
6. Animal models of allergy and preclinical studies with probiotics 
Even though animal models do not completely recapitulate all clinical, histological and 
immunological features of human AD, they can offer valuable tools (i) to evaluate 
candidate probiotic strains and their ability to prevent/alleviate AD and (ii) to elucidate 
their cellular and molecular mechanisms of action. Indeed, assessing the effect of probiotic 
candidate strains directly in human trials is expensive and time-consuming. Moreover, 
the number of candidate strains, the importance of their preparation/formulation, the 
dose, routes and possible administration regimens/schedules increase the number of 
parameters to be evaluated before to launch a clinical trial. Also, food and safety agencies 
recommend to better characterize the mechanism of action of potential probiotics. Since 
access to biological materials other than blood is limited and functional studies are 
difficult to perform in human trials, research on probiotics may benefit from preclinical 
animal models (Kalliomaki et al., 2010).  
In the context of AD, several animal models are used nowadays (Jin et al., 2009) (table 1). 
The historical model of Nc/Nga mice that spontaneously develop AD-like features has been 
commonly used to evaluate the capacity of candidate strains to prevent/manage AD 
(Matsuda et al., 1997). In this model, Nc/Nga mice housed under specific pathogen free 
conditions are protected from AD. Once these mice are transferred to air-unregulated 
conventional environment, they exhibit AD-like lesions by 7-8 weeks. Feeding (heat-treated) 
Lactobacillus rhamnosus GG or live Lactobacillus johnsonii NCC533 around weaning period 
prevented or delayed the onset of AD (Sawada et al., 2007; Tanaka et al., 2008). Offsprings 
exhibited lower clinical scores with shorter scratching duration/frequency, a reduced total 
IgE serum titer and a decreased number of mast cells infiltrating skin lesions. One of the 
caveats of the model of Nc/Nga mice is that the allergen is unknown. To circumvent this 
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Table 1. Common preclinical models of AD (adapted from (Jin et al., 2009)) 
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drawback, modified models have been set up. Repeated application of house dust mite 
Dermatophagoides farina extract induces human-like atopic skin lesions (Huang et al., 2003a). 
In this model, oral administration of live Lactobacillus plantarum from Kimchi, a traditional 
Korean fermented food (Won et al., 2011), or of live L. johnsonii NCC533 alleviated AD 
symptoms (Inoue et al., 2007). In another Nc/Nga-derived model, mice were sensitized by 
epicutaneous application of the hapten picryl chloride, and oral administration of heat-
treated Lactobacillus breve SBC8803 delayed the development of AD (Segawa et al., 2008). It is 
noteworthy that most of these experiments have been performed in young mice with 
administration of probiotics around weaning. However recent papers started to investigate 
the impact of different intervention periods. In this respect, a protective effect of live L. 
rhamnosus LPR was observed when the strain was fed to pregnant dams and their pups for 
12 weeks. Protection was equally seen when probiotic treatment started at weaning but not 
when it was initiated one week after the onset of the disease (Tanaka et al., 2009).  
The general hypothesis evoked to explain the beneficial effect of specific probiotic strains in 
allergy mouse models is their capacity to establish or restore the Th1/Th2 balance. Indeed, 
allergic disorders such as AD are characterized by an immune response that is Th2-biased 
with increased production of cytokines IL-4, IL-5 and IL-13. Investigators working in the 
probiotic field thus started to screen strains according to their ability to polarize T cells 
responses into Th1 responses (with IL-12 and INFγ production) (Mohamadzadeh et al., 
2005) and to induce regulatory T cells (Hacini-Rachinel et al., 2009).  
Alternative models such as the canine model of AD might be of interest as the latter, for ex., 
displays features similar to human AD. Of note, Marsella et al. evaluated the efficacy of L. 
rhamnosus GG in the prevention of canine AD but no significant decrease in clinical 
symptoms was observed (Marsella, 2009).  
7. Probiotics and allergy: Clinical studies 
Studies have been conducted comparing the gut microbiota of infants with AD or food 
allergy to non-allergic infants and in these studies it was observed that allergic infants had 
reduced numbers of lactobacilli and bifidobacteria species in their gut (Adlerberth et al., 
2007; Kirjavainen et al., 2002; Penders et al., 2007). A little more than a decade ago the first 
studies were published testing the hypothesis that probiotic intervention either in the pre- or 
post- natal period (pregnant women, offsprings or both) could influence the incidence of AD 
in the early years of life. Over 25 published studies have investigated similar hypotheses 
since then. However, these studies have largely differed in the choice of probiotic strain 
investigated, duration of administration of the strain, the population treated (mothers vs. 
newborns vs. both mothers and newborns) and in selecting the primary outcome addressing 
the efficacy of the trial. We have grouped the studies into 2 types- those in which the 
probiotic is given as a prevention strategy i.e. in at risk population (history of atopy in the 
family) and the others in which probiotics are administered as a therapeutic entity in 
subjects diagnosed with AD to better manage their symptoms. 
7.1 Prevention of AD 
Around 15 clinical trials have investigated the efficacy of probiotic in prevention of AD 
(summarized in Table 2). We highlight some of the more relevant well designed trials that 
raised key questions in the field of probiotics. Kalliomaki et al. conducted the first long-term 
preventive study on probiotics in AD and found that supplementation with the L. rhamnosus  
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Table 2. Prevention Studies in AD with Probiotics (R= randomized; DB= double blinded; 
PC= placebo controlled) 
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GG strain both to mothers (history of atopic diseases) prenatally in the last 2-4 weeks of 
pregnancy and subsequently to infants from birth to 6 months significantly reduced the 
incidence of AD at 2 years of age, i.e. 15/64 subjects were confirmed AD patients in the 
probiotic group compared to 31/68 in the placebo control group. Interestingly enough, IgE 
levels and skin prick test (SPT) reactivity to common food- and aero-allergens were not 
different between the groups at 2 years (Kalliomaki et al., 2001). The same authors 
conducted a follow-up of the subjects till 4 and 7 years of age and documented the incidence 
of other allergic disorders (allergic rhinitis, asthma) in addition to the long term effect of 
probiotic treatment on AD incidence. At both the follow up time-points, i.e. 4 and 7 years, 
the incidence of AD was lower in the probiotic treated group compared to the placebo 
group (Kalliomaki et al., 2003; Kalliomaki et al., 2007). Yet, the incidence of respiratory 
allergies at the follow-up time periods seemed to be higher in the probiotic treated group. 
The link between probiotic administration early on in life and the development of later onset 
of allergies deserves to be further investigated. A subsequent study evaluating the L. 
rhamnosus GG strain in similar clinical trial settings reported no preventive effect on the 
development of AD at 2 years of age (Kopp et al., 2008). Possibly the beneficial effects of 
probiotic strains are influenced by variants such as diet and genetic heterogeneity in the 
target population or the strain preparation/formulation.  
With the increasing interest in the field of probiotics, various strains were reported to 
display established or potential benefit for allergy management. In this scope, it may 
become important to compare the efficacy of different strains in the same clinical trial. 
Wickens et al. did exactly that and compared the efficacy of L. rhamnosus HN001 and B. lactis 
HN109 to a placebo; reduction in the incidence of AD at 2 years of age was observed with L. 
rhamnosus HN001 but not with B. lactis HN109 in comparison to the placebo, which 
constitutes a quite convincing result (Wickens et al., 2008). Combinations of multiple strains 
have also been attempted in AD clinical trials; Soh et al. combined two strains B. longum 
BL999 and L. rhamnosus GG (LPR), and found that in comparison to the placebo there was 
no significant effect in the reduction of AD incidence at 1 year of age (Soh et al., 2009). It 
should be emphasized that combination of different probiotic candidates or increasing the 
probiotic dose does not necessarily lead to an increased beneficial effect. 
7.2 Therapy: Management of AD symptoms 
Compared to prevention studies, probiotic trials in management of AD are relatively of 
shorter duration (typically 4-12 weeks) and aim at reducing the severity of AD. The primary 
outcome selected is often a change in SCORAD index which is a validated clinical scoring 
system that evaluates the intensity, severity of disease and quality of life parameters 
associated with AD symptoms. AD usually manifests at around 3-4 months of age and 
resolves in about 50% of the AD subjects by 2-3 years of age. As such it is often a challenge 
to demonstrate superiority of treatment compared to the placebo in these trials, as the 
baseline parameters improve spontaneously in part of the enrolled subjects since they are 
already on eviction diet and standardized treatments. Current data with probiotics in the 
management of AD is limited even though the first studies were reported almost 15 years 
ago (Majamaa and Isolauri, 1997).  
Most studies supplement infant formulas that are extensively hydrolyzed with their choice 
of probiotic strains to demonstrate efficacy of probiotics over placebo (non supplemented 
formula). Extensively hydrolyzed formulas are a common dietary recommendation for  
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Table 3. Management studies in AD with probiotics (R= randomized; DB= double blinded; 
PC= placebo controlled) 
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infants with AD manifestations linked to cow’s milk allergy and are largely effective in 
reducing the severity of AD. To demonstrate an improvement with probiotic 
supplementation is by itself a challenging primary outcome. Different strains have been 
evaluated in pilot clinical trials (Table 3) with mixed results. Isolauri et al. showed that both 
L. rhamnosus LGG and B. lactis Bb12 were effective in reducing the severity of AD (Isolauri et 
al., 2000). Interestingly, in a recent publication LGG was however shown to have no effect 
on AD severity (Nermes et al., 2011). 
The selection of the target population also plays a major role in the success of these trials. 
Weston et al. demonstrated the efficacy of L. fermentum PCC in a cohort of subjects with 
moderate to severe AD while other studies have typically selected mild to moderate AD 
subjects and have not succeeded in showing the efficacy of the probiotic strains (Weston et 
al., 2005). Combinations, with other strains or with prebiotics have been attempted with a 
variable success. For example, van der Aa et al. evaluated a combination of B. breve M-16V 
with a prebiotic mixture. After 12 weeks, the severity of atopic dermatitis (AD) did not differ 
between the two groups, indicating no superiority of the synbiotic combination of (pro- and 
pre-biotic) over placebo (van der Aa et al., 2010).  
8. Conclusion 
Probiotics in general are widely available and advertised for numerous health benefits 
ranging from infectious and inflammatory disorders - including allergy -, gut health to 
cognitive performance and skin health. However, the level of available or supporting 
scientific evidence varies widely depending on the studied probiotic strain and its proposed 
health benefit. Since numerous pre-clinical studies and clinical trials have examined the 
efficacy of candidate strains in different models and target populations, it is not possible to 
make the general conclusion that “probiotics” work at large for this or that purpose. As 
discussed in the chapter, health benefits or immune effects are strikingly strain specific, 
which means that observations made on one strain cannot be extrapolated, unless proven, to 
any other strain. As reviewed recently by Kalliomäki et al. (Kalliomaki et al., 2010), 
particularly for AD, taking into account the pre-clinical studies and clinical trials done, it is 
too early for the scientific community to recommend a general use of probiotics in routine 
clinical practice, even though specific strains have been developed with success. The meta-
analyses that have been performed on probiotics and health benefits  often include results of 
clinical trials conducted with different strains in different formats (probiotic powders or 
strains included in a fermented food), in different settings (prevention or treatment) 
targeting different populations (at risk or diseased people, varying age populations) and 
relying on different administration regimes (dose, timing, length of the treatment). Yet, a 
beneficial effect has been reported typically in the case of necrotizing enterocolitis or 
antibiotic-associated diarrheas. For allergy, the situation is complicated by the fact that 
this disease corresponds to a syndrome covering multiple manifestations that are 
influenced by several factors -including environmental ones- that may impact on the onset 
or the perpetuation of the disease (Prescott and Bjorksten, 2007). The meta-analyses 
conducted so far diverge somewhat in their conclusions even if they agree on the fact that 
the evidence is better for allergy prevention than for treatment (Doege et al., 2011; 
Kalliomaki et al., 2010). In 2008, ILSI Europe organized an expert meeting to establish 
guidance for assessing the probiotic beneficial effects and to propose how to fill the gap in 
the areas of digestive system metabolism, chronic intestinal disorders, infections and 
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allergic diseases and the conclusions of this work have been published (The journal of 
Nutrition, 140, Number 3S-I, supplement). Potential avenues for optimizing clinical trials 
in the field of probiotics and allergy, and caveats that may lead to misinterpretation of 
overall results were outlined (Kalliomaki et al., 2010). 
A few studies point to the fact that probiotics may work only on IgE-mediated AD. These 
results although are based on (often retrospective) sub-grouping of the target population 
into IgE vs. non-IgE groups. Clinical trials are needed in the future specifically in large 
enough cohorts of IgE-mediated AD to substantiate this hypothesis. 
Even though several probiotic candidate strains have been tested in vitro and in preclinical 
models of AD, it remains difficult to discuss the predictive value of these preclinical studies. 
Indeed there has not been sufficient alignment between the strains used for clinical trials 
and the ones used for preclinical studies. However, the preclinical models can certainly 
serve the purpose of (i) further understanding the mechanisms of action of specific strains 
that have been found to be beneficial in AD clinical trials, (ii) evaluating the best 
intervention window(s) (prenatal, perinatal, weaning, later in life), (iii) performing dose-
response curves and (iv) analyzing the impact of probiotic preparation/formulation or 
inclusion in a final product, to assess combinations of anti-allergy ingredients, and (v) 
supporting the dossier to submit for approval by ethical committees for human trials. 
In conclusion, when analyzing the results of past and ongoing clinical trials performed with 
probiotics and allergy, it should be kept in mind that AD is a complex multifactorial disease 
whose onset or outcome may strongly depend on the complex interplay between the host, in 
particular its genetic background, the status of the immune system and intestinal 
microbiota, and environmental factors. Nevertheless, additional efforts in the area deserve 
to be pursued as nutritional interventions remain by themselves an interesting approach to 
manage allergic manifestations.  
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